Additionally, the IBD group had lower prior Fidaxomicin use (6.9% vs. 26.3%, p = 0.021) and fewer users of HMG-CoA reductase inhibitors (0.0% vs. 15.5%, p = 0.025). Here, HMGCR is linked to inflammatory bowel disease.